Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Accumulated Expenses (2016 - 2025)

Phibro Animal Health (PAHC) has 12 years of Accumulated Expenses data on record, last reported at $23.3 million in Q2 2025.

  • For Q2 2025, Accumulated Expenses rose 195.54% year-over-year to $23.3 million; the TTM value through Jun 2025 reached $23.3 million, up 195.54%, while the annual FY2025 figure was $23.3 million, 195.54% up from the prior year.
  • Accumulated Expenses reached $23.3 million in Q2 2025 per PAHC's latest filing, down from $30.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $86.4 million in Q2 2021 and bottomed at $6.5 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $41.0 million, with a median of $28.3 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 3632.89% in 2021, then crashed 91.75% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $86.4 million in 2021, then decreased by 20.47% to $68.7 million in 2022, then crashed by 61.21% to $26.6 million in 2023, then increased by 12.5% to $30.0 million in 2024, then decreased by 22.37% to $23.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $23.3 million in Q2 2025, $30.0 million in Q3 2024, and $7.9 million in Q2 2024.